The Oxford-AstraZeneca vaccine was a critical part of the Covid-19 pandemic response. However, on May 7, 2024, the European Commission announced the vaccine is no longer authorised for use.
This European Union announcement was preceded by an application from AstraZeneca on March 27 to withdraw the EU marketing authorisation. This development has been covered in various media outlets as primarily related to the known “adverse events”, namely a very small risk of blood clots. However, other factors are far more likely to be driving this decision.
The first AstraZeneca vaccine dose, outside of clinical trials, was administered on January 4, 2021. In that year, about 2.5 billion doses were administered, and an estimated 6.3 million lives saved.
It was a key product at the peak of the pandemic. This includes during the emergence of the delta variant in India, across the first half of 2021 where, amid significant global supply issues, the AstraZeneca vaccine was one of the few tools available during that humanitarian crisis.
This Covid vaccine, like those from Pfizer, Moderna, Novavax and others, went through the appropriate levels of testing. The phase 3 trials (where the vaccine is tested on thousands of people) showed the AstraZeneca product was safe and effective. It was distributed in many countries in Europe in early 2021, including the UK.
The potential adverse events...
from Scroll.in https://scroll.in/article/1067689/astrazeneca-vaccine-was-key-part-of-global-covid-19-response-but-plagued-by-misinformation?utm_source=rss&utm_medium=public https://sc0.blr1.cdn.digitaloceanspaces.com/article/156711-xcarwdxuik-1616660102.jpg
via
0 Comments